(IN BRIEF) AstraZeneca has entered into a collaboration and investment agreement with biotech firm Cellectis to fast-track the development of cutting-edge therapeutics in areas such as oncology, immunology, and rare diseases. This partnership will leverage Cellectis’ gene editing technologies and … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adrian Kemp, André Choulika, AstraZeneca, Cellectis, gene therapy, immunology, Marc Dunoyer, oncology, partnership, rare diseases, sustainability
(IN BRIEF) Alexion, in collaboration with AstraZeneca Rare Disease, has finalized an agreement to acquire a collection of preclinical rare disease gene therapy programs and related technologies from Pfizer Inc. This strategic move combines the expertise of Alexion and AstraZeneca … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, United Kingdom
Tagged acquisition, Adrian Kemp, Alexion, AstraZeneca, AstraZeneca Rare Disease, gene therapy, genomic medicine, partnership, Pfizer
(IN BRIEF) Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company owned by Bayer AG, has begun the Phase 1/Phase 2 LION-CS101 clinical trial for patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The trial is evaluating AB-1003 (LION-101), an investigational … Read the full press release
Not intended for U.S. and UK Media (IN BRIEF) Bayer AG has partnered with Acuitas Therapeutics, Inc. to enhance its gene therapy portfolio. Acuitas’ lipid nanoparticle (LNP) delivery technology will enable targeted and efficient delivery of gene editing RNA components … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech
Tagged Acuitas Therapeutics, AskBio, Asklepios BioPharmaceutical, Bayer, Clinically validated, components, DNA, Dr. Thomas Madden, Friedemann Janus, gene editing, gene therapy, High potency ionizable lipid technology, Jost Reinhardt, lipid nanoparticle, LNP, LNP carriers, messenger RNA, molecular therapeutics, mRNA, RNA, vivo gene editing
(PRESSEMITTEILUNG) STOCKHOLM, 22-Jun-2022 — /EuropaWire/ — EQT AB, eine zweckorientierte globale Investmentgesellschaft, hat die Übernahme von SPT Labtech bekannt gegeben von Battery Ventures, einer globalen, technologieorientierten Investmentgesellschaft, für 650 Mio. GBP (~ 756 Mio. EUR). SPT Labtech ist ein britisches … Read the full press release
Posted in Business, Investment, Management, Science, Sweden, Technology
Tagged automated liquid handling, Battery Ventures, BCG, cell therapy, Charles Russell Speechlys, Cryo-EM, David Newble, Deloitte, EQT, EQT Private Equity, Evercore, gene therapy, J.P. Morgan, Kirkland & Ellis, life science research, Life Science Tools, liquid handling, Michael Bauer, miniaturization trends, mRNA, Ringstone, sample preparation, SecondSight Law, SPT Labtech, storage instruments, The Footprint Firm, TTP Group
(PRESS RELEASE) STOCKHOLM, 22-Jun-2022 — /EuropaWire/ — EQT AB, a purpose-driven global investment organization, has announced the acquisition of SPT Labtech from Battery Ventures, a global, technology-focused investment firm, for GBP 650 million (~ EUR 756 million). SPT Labtech is … Read the full press release
Posted in Business, Industrial, Investment, Management, News, Science, Sweden, Technology
Tagged automated liquid handling, Battery Ventures, BCG, cell therapy, Charles Russell Speechlys, Cryo-EM, David Newble, Deloitte, EQT, EQT Private Equity, Evercore, gene therapy, J.P. Morgan, Kirkland & Ellis, life science research, Life Science Tools, liquid handling, Michael Bauer, miniaturization trends, mRNA, Ringstone, sample preparation, SecondSight Law, SPT Labtech, storage instruments, The Footprint Firm, TTP Group
Agreement strengthens Bayer’s new cell and gene therapy platform further / Supports Mammoth’s vision of unlocking the full potential of novel CRISPR systems / Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged Bayer AG, Cas enzymes, Cas14, Casɸ, cell therapy, CRISPR, Dr. Imke Meyer, Dr. Peter Nell, gene augmentation, gene editing, gene therapy, gene-editing technology, gene-editing therapies, iPSC, liver diseases, Mammoth Biosciences, Mohana Ray, pluripotent stem cell, Stefan Oelrich, vivo projects
New data show pre-symptomatic babies with spinal muscular atrophy (SMA) treated with Evrysdi maintained the ability to swallow Evrysdi has demonstrated consistent clinically meaningful efficacy in adults, children, and babies two months and older and is now approved in 58 countries worldwide Further … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged DMD, Duchenne muscular dystrophy, Endeavor, Evrysdi, gene therapy, Hammersmith Infant Neurological Examination, HINE-2, Levi Garraway, M.D. Ph.D, motor milestones, neuromuscular, RAINBOWFISH study, risdiplam, Roche, Sarepta, SMA, spinal muscular atrophy, SRP-9001, World Muscle Society (WMS) Virtual Congress
(PRESS RELEASE) SINGAPORE, 22-Jul-2021 — /EuropaWire/ — Kuehne+Nagel, one of the world’s leading logistics companies, has announced that its subsidiary QuickSTAT has opened a new control tower and conditioning facility in Singapore. The investment is part of Kuehne+Nagel and QuickSTAT’s … Read the full press release
Posted in Business, Healthcare, Industrial, Infrastructure & Utilities, News, Pharma & Biotech, Switzerland, Transportation & Logistics
Tagged biologics, biomedical science hub, cell therapy, clinical research samples, clinical trial logistics, clinical trial supplies, conditioning facility, control tower, Cyril Leger, gene therapy, Healthcare, Healthcare Logistics, investigational drugs, investment, Jack Liu, Kuehne+Nagel, logistics, pharma, pharmaceutical product lifecycle, QuickSTAT, Singapore, time and temperature shipping, vaccines
(PRESS RELEASE) LONDON, 27-Mar-2019 — /EuropaWire/ — The LentiGlobin application for Conditional Marketing Authorization (cMAA) at the EMA from bluebird bio is still in the process of being reviewed by CHMP during their 25-28 March 2019 meeting. An opinion for … Read the full press release
Posted in European Union, Healthcare, Italy, News, Pharma & Biotech, Science
Tagged AVLT, CHMP, cMAA, Dr. Chris Sotirelis, Dr. Michele Lipucci di Paola, EMA, gene therapy, LentiGlobin, Thalassaemia, UKTS
OXFORD, 22-Mar-2017 — /EuropaWire/ — Researchers have started a new gene therapy clinical trial to treat X-linked retinitis pigmentosa (XLRP), the most common cause of blindness in young people. Retinitis pigmentosa is currently untreatable and leads to a slow and irreversible … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged David Fellows, Dr Aniz Girach, gene therapy, Nightstarx Ltd, Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Professor Robert MacLaren, Robert MacLaren, Treatment of Genetic Blindness, University of Oxford
EMA invites feedback on its new draft guideline LONDON, 22-5-2015 — /EuropaWire/ — The European Medicines Agency (EMA) has released a draft guideline on quality, non-clinical and clinical aspects of gene therapies for a three-month public consultation. The document aims … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
